IPIX MM Monthly ~ May 2018 May 2018 ~ volume total ~

New Post Public Reply Private Reply Replies (2) Message Board
4kids 4kids #45393
695
IPIX MM Monthly ~ May 2018

May 2018 ~ volume total ~ 5,542,951
(link back for April 2018 data)

there were 11 MMs/ECNs' reporting *activity* on IPIX .. in order:
ETRF/NITE/CDEL (32%/23%/22%)
CSTI/LAFC/ARCA/OTCX/VERT (5%/4%/4%/4%/3%)
CANT/MAXM/PUMA .. all less then 1%

amazing how much of a *decoy* both VERT & OTCX *were* ..

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 
IPIX Innovation Pharma 5,542,951 4,473,436 22,616,572 ETRF G1 EXECUTION SVCs, LLC 1,779,590 1 32.11
IPIX Innovation Pharma 5,542,951 4,473,436 22,616,572 NITE VIRTU AMERICAS LLC 1,288,265 2 23.24
IPIX Innovation Pharma 5,542,951 4,473,436 22,616,572 CDEL CITADEL SECURITIES LLC 1,224,386 3 22.09


it's been just about a year since mgmt's upside surprise in June 2017 .. here's the Monthly Volume Totals broken down by month .. take note of the *overlapping* similarities

JUN 2017 ~ 6,863,055
JUL 2017 ~ 4 ,896,207
AUG 2017 ~ 3 ,276,355
SEP 2017 ~ 2,395,379
OCT 2017 ~ 3 ,856,915
NOV 2017 ~ 4,0 31,082
DEC 2017 ~ 8,121,069
JAN 2018 ~ 5 ,133,221
FEB 2018 ~ 3 ,388,387
MAR 2018 ~ 4,0 78,577
APR 2018 ~ 4 ,473,436
MAY 2018 ~ 5 ,542,951

http://otce.finra.org/MonthlyShareVolume

during that same year long period .. *legal* had to be adjusted *upward* ..
(see below) .. but first .. i pulled the data (historical .. pps and volume avgs) from mid month for the last year >> to show patterns done on IPIX ..

5.15.17 ( markage @ 41% )
Detailed Quote:CTIX
CELLCEUTIX CORPORATION
0.82825Up 0.11825 (16.65 %) AS OF 3:58:26PM ET 05/15/2017


Volume 547,948
Volume (10 day Average) 140,183
Volume (90 day Average) 278,946


6.15.17 ( markage @ 24% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.76Up 0.02 (2.70 %)AS OF 3:57:28PM ET 06/15/2017


Volume 224,876
Volume (10 day Average) 336,072
Volume (90 day Average) 267,023


7.17.17 ( markage @ 23% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.972Down -0.068 (-6.54 %) AS OF 3:59:15PM ET 07/17/2017


Volume 249,885
Volume (10 day Average) 286,095
Volume (90 day Average) 276,468


8.15.17 ( markage @ 27% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.785Up 0.0565 (7.76 %) AS OF 3:57:24PM ET 08/15/2017


Volume 76,529
Volume (10 day Average) 161,964
Volume (90 day Average) 268,908


9.15.17 ( markage @ 22% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.72Up 0.0095 (1.34 %) AS OF 3:59:51PM ET 09/15/2017


Volume 223,443
Volume (10 day Average) 100,122
Volume (90 day Average) 227,459


10.16.17 ( markage @ 38% ) .. cracks starting to *show* (see below)
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.68Down -0.01 (-1.45 %) AS OF 3:59:59PM ET 10/16/2017


Volume 113,405
Volume (10 day Average) 168,465
Volume (90 day Average) 197,664


11.15.17 ( markage @ 15% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.69Down -0.015 (-2.13 %) AS OF 3:59:04PM ET 11/15/2017


Volume 163,194
Volume (10 day Average) 172,115
Volume (90 day Average) 164,764


12.15.17 ( markage @ 26% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.785Up 0.00705 (0.91 %) AS OF 3:59:57PM ET 12/15/2017


Price Performance (Last 52 Weeks)
12/14/2017 -32.35%


Volume 153,680
Volume (10 day Average) 563,214
Volume (90 day Average) 202,489


1.16.18 ( markage @ 32% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.7249Up 0.0149 (2.10 %) AS OF 3:59:25PM ET 01/16/2018


Price Performance (Last 52 Weeks)
01/12/2018 -39.06%


Volume 300,052
Volume (10 day Average) 244,424
Volume (90 day Average) 224,823


2.15.18 ( markage @ 36% ) ** 52 week low reset 2.22.18 (5.10.17)
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.69Up 0.005 (0.73 %) AS OF 3:56:07PM ET 02/15/2018


Price Performance (Last 52 Weeks)
02/14/2018 -31.50%


Volume 115,948
Volume (10 day Average) 159,451
Volume (90 day Average) 243,268


3.15.18 ( markage @ 27% )
DETAILED QUOTE:IPIX
INNOVATION PHARMACEUTICALS INC
0.57Down -0.03 (-5.00 %) AS OF 3:55:43PM ET 03/15/2018


PRICE PERFORMANCE (LAST 52 WEEKS)
03/14/2018 -35.48%


VOLUME 329,874
VOLUME (10 DAY AVERAGE) 210,605
VOLUME (90 DAY AVERAGE) 251,097


4.16.18 ( markage @ 57% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.50Down -0.007 (-1.38 %) AS OF 3:59:59PM ET 04/16/2018


Volume 295,972
Volume (10 day Average) 151,331
Volume (90 day Average) 243,964


5.15.18 ( markage @ 50% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.59005Up 0.15405 (35.33 %) AS OF 3:59:48PM ET 05/15/2018


Volume 384,483
Volume (10 day Average) 335,770
Volume (90 day Average) 218,697



===========================================

*legal* reported by NR on CTIX/IPIX since Jan 2017 ~ remember NR reset 52 week low on IPIX on 5.10.17 .. approx 1 month later mgmt did a *surprise* to NR by changing out name/ticker and cusip .. which took NR until 2.22.18 to *reset* ..

spot the *pattern* NR deployed on IPIX re: their *reporting* .. .. and note the whoppers' reported re: avg daily volume by NR .. Dec 2017 (among other months) comes to mind .. btw that *reporting* would *impact* those *days to cover* also *reported* by NR .. go figure



Settlement Date
Issue Name
Symbol
Market
Current Short
Previous Short
Chg
% Change from Prev
Avg Daily Vol
Days to Cover

 
05/15/2018 Innovation Pharma IPIX 1,194,881 1,113,653 81,228 7.29 677,661 1.76
04/30/2018 Innovation Pharma IPIX 1,113,653 1,131,509 -17,856 -1.58 536,933 2.07
04/13/2018 Innovation Pharma IPIX 1,131,509 1,105,305 26,204 2.37 302,523 3.74
03/29/2018 Innovation Pharma IPIX 1,105,305 1,107,705 -2,400 -0.22 328,260 3.37
03/15/2018 Innovation Pharma IPIX 1,107,705 1,146,037 -38,332 -3.34 442,762 2.5
02/28/2018 Innovation Pharma IPIX 1,146,037 1,147,767 -1,730 -0.15 419,357 2.73
02/15/2018 Innovation Pharma IPIX 1,147,767 1,122,033 25,734 2.29 310,620 3.7
01/31/2018 Innovation Pharma IPIX 1,122,033 1,121,161 872 0.08 494,222 2.27
01/12/2018 Innovation Pharma IPIX 1,121,161 1,119,374 1,787 0.16 479,712 2.34
12/29/2017 Innovation Pharma IPIX 1,119,374 1,125,087 -5,713 -0.51 517,994 2.16
12/15/2017 Innovation Pharma IPIX 1,125,087 1,129,343 -4,256 -0.38 1,046,247 1.08
11/30/2017 Innovation Pharma IPIX 1,129,343 1,140,375 -11,032 -0.97 428,497 2.64
11/15/2017 Innovation Pharma IPIX 1,140,375 1,274,605 -134,230 -10.53 342,258 3.33
10/31/2017 Innovation Pharma IPIX 1,274,605 1,227,218 47,387 3.86 361,557 3.53
10/13/2017 Innovation Pharma IPIX 1,227,218 1,214,663 12,555 1.03 335,578 3.66
09/29/2017 Innovation Pharma IPIX 1,214,663 1,214,089 574 0.05 262,229 4.63
09/15/2017 Innovation Pharma IPIX 1,214,089 1,220,108 -6,019 -0.49 215,861 5.62
08/31/2017 Innovation Pharma IPIX 1,220,108 1,226,343 -6,235 -0.51 262,819 4.64
08/15/2017 Innovation Pharma IPIX 1,226,343 1,206,257 20,086 1.67 307,793 3.98
07/31/2017 Innovation Pharma IPIX 1,206,257 1,302,241 -95,984 -7.37 389,777 3.09
07/14/2017 Innovation Pharma IPIX 1,302,241 1,458,432 -156,191 -10.71 609,859 2.14
06/30/2017 Innovation Pharma IPIX 1,458,432 1,234,237 224,195 18.16 594,048 2.46
06/15/2017 Innovation Pharma IPIX 1,234,237 1,161,877 72,360 6.23 650,213 1.9

05/31/2017 Cellceutix CTIX 1,161,877 1,037,384 124,493 12 579,670 2.0

 
May 15, 2017 1,037,384 18.46 354,459 2.93 No No
Apr 28, 2017 875,733 -0.07 759,565 1.15 No No
Apr 13, 2017 876,376 3.15 558,853 1.57 No No
Mar 31, 2017 849,619 -1.16 492,310 1.73 No No
Mar 15, 2017 859,596 -2.21 297,012 2.89 No No
Feb 28, 2017 879,016 0.82 796,211 1.10 No No
Feb 15, 2017 871,870 -0.34 373,962 2.33 No No
Jan 31, 2017 874,870 11.57 1,079,666 1.00 No No
Jan 13, 2017 784,114 -1.41 390,950 2.01 No No


NR had worked the cycle of money on CTIX (IPIX) *UP/DOWN* for years .. and most likely figured in early Jan 2015 .. that flip *DOWN* would be no different .. but a funny thing happened .. due to mgmt's ability to execute .. actual investors couldn't be parted from their *shares* and it set up *imo* the *events* by NR in the latter half of 2015 .. which mgmt didn't roll over for .. rather *aggressively responded* to .. and so it's gone since then .. this is why i note that NR is in a hole of their own making .. NR is used to always controlling *outcomes* on the OTC .. right now they have little time and imo even less *liquidity* .. which is why i say they are stuck .. and their *stuckness* is telegraphing itself via a *legal* that is almost amusing to watch *reported* .. bogus daily volume avgs reported re: that *legal* .. and daily *markages* ( % wise ) that keep ratcheting northward .. all this on less and less *volume* .. oh yeah and Innovation's multi platform hanging over NRs' *head* like the sword of damocles .. it couldn't happen to a nicer group of crooks *imo*

in pulling this post together (always time consuming) .. i realized i have the *legal reported* .. since Innovation first started trading .. way back when ..

if i have the time i will try and get that out sometime this week .. it's amazing how NRs' *cycles of money* .. worked for them so well for so long .. but nothing beats an aware OTC mgmt team that executes and an educated retail investor ..

best to all Innovation Pharma investors

4kids
















































Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 84

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 46

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Cruise Line Celebrates Employees as Godparents of Treasure

Updated Category News Views 97

Disney Cruise Line Celebrates Employees in Honor of Disney Treasure Disney Cruise Line is redefining maritime traditions in a beautiful manner by honoring its dedicated employees worldwide. The company’s latest announcement revealed that the honorific role of "godparent" for the new ship, the Disney Treasure, will be shared among its tremendous cast, crew, Imagineers,...

Continue Reading
Regional Management Corp. to Share Q3 2024 Financial Insights

Updated Category News Views 79

Regional Management Corp. to Announce Q3 Results Greenville, S.C. – Regional Management Corp. (NYSE: RM), a prominent player in the consumer finance sector, is set to share its financial results for the third quarter of 2024. Conference Call Details and Replay The company will report its quarterly results after market close, providing investors and stakeholders with...

Continue Reading
Suvoda Recognized as a Leader in Clinical Trial Technology

Updated Category News Views 147

Suvoda Acknowledged as a Leader in RTSM Technology Suvoda, a cutting-edge clinical trial technology company, recently shared exciting news about their IRT (Interactive Response Technology) software, which has been designated as a Leader in the prominent Everest Group's PEAK Matrix assessment for RTSM (Randomization and Trial Supply Management) technology. This recognition...

Continue Reading
Cereno Scientific Expands CS014 Focus to Combat PH-ILD

Updated Category News Views 131

Cereno Scientific Expands CS014 Focus to Combat PH-ILD Cereno Scientific, a pioneering biotech company, has made a significant announcement regarding the development focus of its HDAC inhibitor CS014. This innovative treatment is now targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD), an area marked by a high level of unmet medical need....

Continue Reading
Dysmenorrhea Treatment Market Growth Insights for 2032

Updated Category News Views 188

Global Dysmenorrhea Treatment Market Insights Dysmenorrhea, commonly referred to as menstrual cramps, affects many women globally, causing significant discomfort during their menstrual cycles. Recent trends indicate that as awareness of this condition grows, so does the demand for effective treatments. The global dysmenorrhea treatment market is projected to surpass USD 8...

Continue Reading